Cover Image
Market Research Report

North America Ophthalmic Drugs Market Forecast 2019-2027

Published by Inkwood Research Product code 861608
Published Content info 80 Pages
Delivery time: 2-3 business days
Price
Back to Top
North America Ophthalmic Drugs Market Forecast 2019-2027
Published: June 10, 2019 Content info: 80 Pages
Description

KEY FINDINGS

North America ophthalmic drugs market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 growing at a CAGR of 3.66% during the forecast period of 2019-2027. The ophthalmic drugs and devices market is driven by factors like increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.

MARKET INSIGHTS

The prevalence of blindness and vision impairment and other eye-related disorders is expected to increase rapidly among all age group, gender and racial group in North America. The increase in geriatric population, rise in the number of eye disorders, increase in healthcare expenditure and rise in adoption of minimally invasive surgeries have contributed to the growth of the market in North America.

Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.

COMPETITIVE INSIGHTS

Global ophthalmic drugs market has a large number of market players but the market is dominated by companies like Cipla Pharmaceuticals, Sun Pharmaceuticals Industries, Ltd., Valeant, Apollo Endosurgery, Bayer, Johnson and Johnson, Regeneron, Pfizer Inc., Eyegate Pharmaceuticals, Abbott Laboratories, Novartis AG, Roche Holding AG, Allergan Inc., Senju Pharmaceutical Co., Ltd., GlaxoSmithKline, and Merck & Co.

Table of Contents
Product Code: 25347

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. RETINAL DISORDERS ARE THE HIGHEST REVENUE GENERATING INDICATION
    • 3.2.2. PRESCRIPTION DRUGS ARE THE FASTEST GROWING OPHTHALMIC DRUGS TYPE
    • 3.2.3. HOSPITAL PHARMACIES ARE THE MAJORLY USED DISTRIBUTION CHANNEL
    • 3.2.4. LIQUID OPHTHALMIC DRUG FORMS ARE THE WIDELY USED DOSAGE FORM
    • 3.2.5. ANTI-ALLERGY THERAPEUTIC CLASS IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE DURING THE FORECAST PERIOD
    • 3.2.6. SMALL MOLECULE TECHNOLOGY IS USED FOR THE TREATMENT OF EYE DISEASES

4. MARKET DETERMINANTS

  • 4.1. MARKET DEFINITION AND SCOPE
  • 4.2. MARKET DRIVERS
    • 4.2.1. INCREASING GERIATRIC POPULATION
    • 4.2.2. TECHNOLOGICAL ADVANCEMENT
    • 4.2.3. RISING PREVALENCE OF EYE DISORDERS
    • 4.2.4. INCREASED HEALTHCARE EXPENDITURE
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. RENOWNED DRUGS GOING OFF-PATENT
    • 4.3.2. DELAY IN DRUG APPROVALS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
    • 4.4.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. SIDE EFFECTS RELATED TO THE OPHTHALMIC DRUGS

5. MARKET BY INDICATION

  • 5.1. DRY EYE
  • 5.2. GLAUCOMA
  • 5.3. INFECTION/INFLAMMATION/ALLERGY
  • 5.4. RETINAL DISORDERS
    • 5.4.1. WET AGE-RELATED MACULAR DEGENERATION
    • 5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
    • 5.4.3. DIABETIC RETINOPATHY
    • 5.4.4. OTHER RETINAL DISORDERS
  • 5.5. OTHER INDICATION

6. MARKET BY TYPE

  • 6.1. PRESCRIPTION DRUGS
  • 6.2. OVER-THE-COUNTER DRUGS

7. MARKET BY DISTRIBUTION CHANNEL

  • 7.1. HOSPITAL PHARMACIES
  • 7.2. DRUG STORES
  • 7.3. ONLINE PHARMACIES
  • 7.4. OTHER DISTRIBUTION CHANNEL

8. MARKET BY DOSAGE FORM

  • 8.1. LIQUID OPHTHALMIC DRUG FORMS
  • 8.2. SOLID OPHTHALMIC DRUG FORMS
  • 8.3. SEMISOLID OPHTHALMIC DRUG FORMS
  • 8.4. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
  • 8.5. OTHER OPHTHALMIC DRUG FORMS

9. MARKET BY THERAPEUTIC CLASS

  • 9.1. ANTI-GLAUCOMA
  • 9.2. ANTI-INFECTIVE
  • 9.3. ANTI-INFLAMMATORY
  • 9.4. ANTI-ALLERGY

10. MARKET BY TECHNOLOGY

  • 10.1. BIOLOGICS
  • 10.2. CELL THERAPY
  • 10.3. GENE THERAPY
  • 10.4. DRUG DELIVERY
  • 10.5. SMALL MOLECULE
  • 10.6. OTHER TECHNOLOGY

11. KEY ANALYTICS

  • 11.1. PORTER'S FIVE FORCES ANALYSIS
    • 11.1.1. BARGAINING POWER OF BUYERS
    • 11.1.2. BARGAINING POWER OF SUPPLIER
    • 11.1.3. THREATS OF NEW ENTRANTS
    • 11.1.4. THREATS OF SUBSTITUTES
    • 11.1.5. COMPETITIVE RIVALRY
  • 11.2. VALUE CHAIN ANALYSIS
    • 11.2.1. RESEARCH AND DEVELOPMENT
    • 11.2.2. MANUFACTURING
    • 11.2.3. MARKETING AND DISTRIBUTION
  • 11.3. REGULATORY FRAMEWORK
  • 11.4. OPPORTUNITY MATRIX

12. GEOGRAPHICAL ANALYSIS

  • 12.1. NORTH AMERICA
    • 12.1.1. THE UNITED STATES
    • 12.1.2. CANADA

13. COMPANY PROFILES

  • 13.1. ABBOTT LABORATORIES
  • 13.2. ALLERGAN INC.
  • 13.3. JOHNSON AND JOHNSON
  • 13.4. BAYER
  • 13.5. VALEANT
  • 13.6. REGENERON
  • 13.7. PFIZER INC.
  • 13.8. MERCK & CO.
  • 13.9. NOVARTIS AG
  • 13.10. GLAXOSMITHKLINE
  • 13.11. EYEGATE PHARMACEUTICALS
  • 13.12. APOLLO ENDOSURGERY
  • 13.13. ROCHE HOLDING AG
  • 13.14. CIPLA PHARMACEUTICALS
  • 13.15. SENJU PHARMACEUTICAL CO., LTD.
  • 13.16. SUN PHARMACEUTICALS INDUSTRIES, LTD.

LIST OF TABLES

  • TABLE 1 NORTH AMERICA OPHTHALMIC DRUG MARKET REVENUE 2019-2027 ($ MILLION)
  • TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
  • TABLE 3 EYE DRUGS GONE OFF-PATENT
  • TABLE 4 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 5 NORTH AMERICA DRY EYE MARKET 2019-2027 ($ MILLION)
  • TABLE 6 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DRY EYE 2019-2027 ($ MILLION)
  • TABLE 7 NORTH AMERICA GLAUCOMA MARKET 2019-2027 ($ MILLION)
  • TABLE 8 NORTH AMERICA INFECTION/INFLAMMATION/ALLERGY MARKET 2019-2027 ($ MILLION)
  • TABLE 9 NORTH AMERICA RETINAL DISORDERS MARKET 2019-2027 ($ MILLION)
  • TABLE 10 NORTH AMERICA WET AGE-RELATED MACULAR DEGENERATION MARKET 2019-2027 ($ MILLION)
  • TABLE 11 NORTH AMERICA DRY AGE-RELATED MACULAR DEGENERATION MARKET 2019-2027 ($ MILLION)
  • TABLE 12 NORTH AMERICA DIABETIC RETINOPATHY MARKET 2019-2027 ($ MILLION)
  • TABLE 13 NORTH AMERICA OTHER RETINAL DISORDERS MARKET 2019-2027 ($ MILLION)
  • TABLE 14 NORTH AMERICA OTHER INDICATION MARKET 2019-2027 ($ MILLION)
  • TABLE 15 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 16 NORTH AMERICA PRESCRIPTION DRUGS MARKET 2019-2027 ($ MILLION)
  • TABLE 17 NORTH AMERICA OVER-THE-COUNTER DRUGS MARKET 2019-2027 ($ MILLION)
  • TABLE 18 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)
  • TABLE 19 NORTH AMERICA HOSPITAL PHARMACIES MARKET 2019-2027 ($ MILLION)
  • TABLE 20 NORTH AMERICA DRUG STORES MARKET 2019-2027 ($ MILLION)
  • TABLE 21 NORTH AMERICA ONLINE PHARMACIES MARKET 2019-2027 ($ MILLION)
  • TABLE 22 NORTH AMERICA OTHER DISTRIBUTION CHANNEL MARKET 2019-2027 ($ MILLION)
  • TABLE 23 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DOSAGE FORM 2019-2027 ($ MILLION)
  • TABLE 24 NORTH AMERICA LIQUID OPHTHALMIC DRUG FORMS PHARMACIES MARKET 2019-2027 ($ MILLION)
  • TABLE 25 NORTH AMERICA SOLID OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)
  • TABLE 26 NORTH AMERICA SEMISOLID OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)
  • TABLE 27 NORTH AMERICA MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET 2019-2027 ($ MILLION)
  • TABLE 28 NORTH AMERICA OTHER OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)
  • TABLE 29 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY THERAPEUTIC CLASS 2019-2027 ($ MILLION)
  • TABLE 30 NORTH AMERICA ANTI-GLAUCOMA MARKET 2019-2027 ($ MILLION)
  • TABLE 31 NORTH AMERICA ANTI-INFECTIVE MARKET 2019-2027 ($ MILLION)
  • TABLE 32 NORTH AMERICA ANTI-INFLAMMATORY MARKET 2019-2027 ($ MILLION)
  • TABLE 33 NORTH AMERICA ANTI-ALLERGY MARKET 2019-2027 ($ MILLION)
  • TABLE 34 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
  • TABLE 35 NORTH AMERICA BIOLOGICS MARKET 2019-2027 ($ MILLION)
  • TABLE 36 NORTH AMERICA CELL THERAPY MARKET 2019-2027 ($ MILLION)
  • TABLE 37 NORTH AMERICA GENE THERAPY MARKET 2019-2027 ($ MILLION)
  • TABLE 38 NORTH AMERICA DRUG DELIVERY MARKET 2019-2027 ($ MILLION)
  • TABLE 39 NORTH AMERICA SMALL MOLECULE MARKET 2019-2027 ($ MILLION)
  • TABLE 40 NORTH AMERICA OTHER TECHNOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 41 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY GLAUCOMA 2019-2027 ($ MILLION)
  • FIGURE 2 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY INFECTION /INFLAMMATION /ALLERGY 2019-2027 ($ MILLION)
  • FIGURE 3 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY RETINAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 4 NORTH AMERICA RETINAL DISORDERS MARKET BY WET AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)
  • FIGURE 5 NORTH AMERICA RETINAL DISORDERS MARKET BY DRY AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)
  • FIGURE 6 NORTH AMERICA RETINAL DISORDERS MARKET BY DIABETIC RETINOPATHY 2019-2027 ($ MILLION)
  • FIGURE 7 NORTH AMERICA RETINAL DISORDERS MARKET BY OTHER RETINAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 8 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OTHER INDICATION 2019-2027 ($ MILLION)
  • FIGURE 9 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY PRESCRIPTION DRUGS 2019-2027 ($ MILLION)
  • FIGURE 10 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OVER-THE-COUNTER DRUGS 2019-2027 ($ MILLION)
  • FIGURE 11 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY HOSPITAL PHARMACIES 2019-2027 ($ MILLION)
  • FIGURE 12 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DRUG STORES 2019-2027 ($ MILLION)
  • FIGURE 13 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ONLINE PHARMACIES 2019-2027 ($ MILLION)
  • FIGURE 14 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OTHER DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)
  • FIGURE 15 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY LIQUID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
  • FIGURE 16 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY SOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
  • FIGURE 17 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY SEMISOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
  • FIGURE 18 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS 2019-2027 ($ MILLION)
  • FIGURE 19 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OTHER OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
  • FIGURE 20 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ANTI-GLAUCOMA 2019-2027 ($ MILLION)
  • FIGURE 21 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ANTI-INFECTIVE 2019-2027 ($ MILLION)
  • FIGURE 22 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ANTI-INFLAMMATORY 2019-2027 ($ MILLION)
  • FIGURE 23 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ANTI-ALLERGY 2019-2027 ($ MILLION)
  • FIGURE 24 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY BIOLOGICS 2019-2027 ($ MILLION)
  • FIGURE 25 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY CELL THERAPY 2019-2027 ($ MILLION)
  • FIGURE 26 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY GENE THERAPY 2019-2027 ($ MILLION)
  • FIGURE 27 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DRUG DELIVERY 2019-2027 ($ MILLION)
  • FIGURE 28 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY SMALL MOLECULE 2019-2027 ($ MILLION)
  • FIGURE 29 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OTHER TECHNOLOGY 2019-2027 ($ MILLION)
  • FIGURE 30 THE UNITED STATES POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
  • FIGURE 31 THE UNITED STATES OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 CANADA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 33 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016
Back to Top